Title : Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Pub. Date : 2021 Jun 5

PMID : 34023009






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Upadacitinib is an oral Janus kinase (JAK) inhibitor with greater inhibitory potency for JAK1 than JAK2, JAK3, or tyrosine kinase 2 that is being tested for atopic dermatitis. upadacitinib Janus kinase 2 Homo sapiens